Active-ingredient Dossier
Pioglitazone Hydrochloride
Active-ingredient Dossier for Pioglitazone Hydrochloride (thiazolidinedione antidiabetic agent). Australian brands, products, PBS listings, PBAC outcomes…
- Brand: ACTOS
- Brand: ARX-PIOGLITAZONE
- Brand: VEXAZONE
- Brand: AURO-PIOGLITAZONE
- Brand: AZTYME Tablets
- Brand: PIOPOD
- Therapeutic area: Endocrinology
What is
Pioglitazone Hydrochloride Pioglitazone Hydrochloride is a thiazolidinedione antidiabetic agent.
Australian brands containing
Pioglitazone Hydrochloride — ACTOS — ARX-PIOGLITAZONE — VEXAZONE — AURO-PIOGLITAZONE — AZTYME Tablets — GLITOS — PIOGLIT — PIOGLITAZONE — PIOGLITAZONE CH — PIOGLITAZONE-WGR — PIOPOD — PIOTOR
Therapeutic areas
Pioglitazone Hydrochloride is registered in endocrinology, with 13 brands on the ARTG.
Sponsor landscape
Six sponsors market pioglitazone hydrochloride: Arrotex Pharmaceuticals, Torrent, Accord Healthcare, Generic Health, GM Pharma, and Alphapharm.
PBS and regulatory activity
Two brands containing pioglitazone hydrochloride have PBS-listed items, with the latest PBS schedule date of 1 May 2026. The latest PBAC outcome was recorded on 1 May 2025, with one brand having PBAC outcomes on record.